Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Association Of Pediatric Buccal Epigenetic Age Acceleration With Adverse Neonatal Brain Growth And Neurodevelopmental Outcomes Among Children Born Very Preterm With A Neonatal Infection., Noha Gomaa, Chaini Konwar, Nicole Gladish, Stephanie H Au-Young, Ting Guo, Min Sheng, Sarah M Merrill, Edmond Kelly, Vann Chau, Helen M Branson, Linh G Ly, Emma G Duerden, Ruth E Grunau, Michael S Kobor, Steven P Miller
Association Of Pediatric Buccal Epigenetic Age Acceleration With Adverse Neonatal Brain Growth And Neurodevelopmental Outcomes Among Children Born Very Preterm With A Neonatal Infection., Noha Gomaa, Chaini Konwar, Nicole Gladish, Stephanie H Au-Young, Ting Guo, Min Sheng, Sarah M Merrill, Edmond Kelly, Vann Chau, Helen M Branson, Linh G Ly, Emma G Duerden, Ruth E Grunau, Michael S Kobor, Steven P Miller
Department of Medicine Publications
IMPORTANCE: Very preterm neonates (24-32 weeks' gestation) remain at a higher risk of morbidity and neurodevelopmental adversity throughout their lifespan. Because the extent of prematurity alone does not fully explain the risk of adverse neonatal brain growth or neurodevelopmental outcomes, there is a need for neonatal biomarkers to help estimate these risks in this population.
OBJECTIVES: To characterize the pediatric buccal epigenetic (PedBE) clock-a recently developed tool to measure biological aging-among very preterm neonates and to assess its association with the extent of prematurity, neonatal comorbidities, neonatal brain growth, and neurodevelopmental outcomes at 18 months of age.
DESIGN, SETTING, AND …
2022 Canadian Cardiovascular Society Guideline For Use Of Glp-1 Receptor Agonists And Sglt2 Inhibitors For Cardiorenal Risk Reduction In Adults, G.B. John Mancini, Eileen O'Meara, Shelley Zieroth, Mathieu Bernier, Alice Y.Y. Cheng, David Z.I. Cherney, Kim A. Connelly, Justin Ezekowitz, Ronald M. Goldenberg, Lawrence A. Leiter, Gihad Nesrallah, Breay W. Paty, Marie-Eve Piche, Peter Senior, Abhinav Sharma, Subodh Verma, Vincent Woo, Pol Darras, Jonathan Y. Gabor, Jean Gregoire, Eva Lonn, James A. Stone, Jean-Francois Yale, Colin Yeung, Deborah Zimmerman
2022 Canadian Cardiovascular Society Guideline For Use Of Glp-1 Receptor Agonists And Sglt2 Inhibitors For Cardiorenal Risk Reduction In Adults, G.B. John Mancini, Eileen O'Meara, Shelley Zieroth, Mathieu Bernier, Alice Y.Y. Cheng, David Z.I. Cherney, Kim A. Connelly, Justin Ezekowitz, Ronald M. Goldenberg, Lawrence A. Leiter, Gihad Nesrallah, Breay W. Paty, Marie-Eve Piche, Peter Senior, Abhinav Sharma, Subodh Verma, Vincent Woo, Pol Darras, Jonathan Y. Gabor, Jean Gregoire, Eva Lonn, James A. Stone, Jean-Francois Yale, Colin Yeung, Deborah Zimmerman
Department of Medicine Publications
This guideline synthesizes clinical trial data supporting the role of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors (SGLT2i) for treatment of heart failure (HF), chronic kidney disease, and for optimizing prevention of cardiorenal morbidity and mortality in patients with type 2 diabetes. It is on the basis of a companion systematic review and meta-analysis guided by a focused set of population, intervention, control, and outcomes (PICO) questions that address priority cardiorenal end points. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system and a modified Delphi process were used. We encourage comprehensive assessment of cardiovascular (CV) patients …